email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2637-4579

Open Access Journal of Biomedical Engineering and Biosciences

Review Article(ISSN: 2637-4579)

Diabetes, Dipeptidyl Peptidase IV and Wound Healing: from Basic Science to Therapeutic Possibilities

Volume 2 - Issue 5

Lara Baticic Pucar1*, Alaa Sharbini2, Jadranka Varljen1, Ester Pernjak Pugel3, Antonijo Grcic2 and Dijana Detel1

  • Author Information Open or Close
    • 1Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Croatia
    • 2Student at the Faculty of Medicine, University of Rijeka, Croatia
    • 3Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Croatia

    *Corresponding author: Lara Baticic Pucar, Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia

Received: August 30, 2018;   Published: September 10, 2018

DOI: 10.32474/OAJBEB.2018.02.000147

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Diabetes mellitus, a chronic metabolic disease characterized by different pathological outcomes as a consequence of unsettled hyperglycemia, often accompanied with various complications such as chronic ulcers, represents a major socio-economic health problem. Dipeptidyl peptidase IV or CD26 molecule (DPP IV/CD26), is an omnipresent transmembrane protein with significant involvements in different physiological and pathological processes. It has been recognized as a therapeutic option in the treatment of hyperglycemia, especially in patients suffering from type 2 diabetes, given its capability to regulate the biological activity of incretins, which are major regulators of glucose homeostasis. Furthermore, DPP IV/CD26 has been indicated to be involved in the regulation of inflammatory processes as well as cell proliferation and angiogenesis. New scientific evidence shows that inhibition of DPP IV/CD26 leads to a more efficacious healing of chronic ulcers in diabetic patients as well as in mice models of wounded tissue restoration. However, the role of DPP IV/CD26 in the process of wound healing in hyperglycemia is not entirely known. Our aim was to summarize most important findings on the involvement of DPP IV/CD26 in the regulation of glycemia as well as tissue regeneration and reparation. This work reviews basic biochemical mechanisms and therapeutic possibilities of DPP IV/CD26 inhibition as a good candidate in the therapy of diabetic wound healing.

Keywords: CD26 molecule; Diabetes; Dipeptidyl-peptidase IV; Hyperglycemia; Chronic Metabolic Disease; Wound healing; Glucose Homeostasis

Abstract| Introduction| Acknowledgment References|


Online Submission System

Drag and drop files here


Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )